The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Anti-PD-1 antibody treatment for melanoma
Open accessOverview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The observed objective response rate was higher than rates reported for melanoma patients primarily refractory to anti-PD-1 who were treated beyond progression.
“the observed ORR was superior to ORRs reported in melanoma patients primary refractory to anti–PD-1 therapy treated beyond progression (17).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [17]
Citations
Cites
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069
Self-citationHodi, F. S., Hwu, W., Kefford, R. F., Weber, J. S., DAUD, A. I., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 738
Self-citationBeaver, J. A., Hazarika, M., Mulkey, F. A., Mushti, S. L., Chen, H., He, K., Sridhara, R., Goldberg, K. B., Chuk, M. K., Chi, D.-C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30846-x · Cited by 168
Flagged first, then by citations
Cited by
Sorted by citations
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781
Self-citationFecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Ribas, A., Medina, T., Kirkwood, J. M., Zakharia, Y., Gonzalez, R., Davar, D., Chmielowski, B., Campbell, K. M., Bao, R., Kelley, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0425 · Cited by 180
Self-citationLiu, Z., Liu, W., Wang, W., Ma, Y., Wang, Y., Drum, D. L., Cai, J., Blevins, H., Lee, E., Shah, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2302878120 · Cited by 116
Chen, K., Wang, X., Yang, L., & Chen, Z. (2021) · Cancer Control · doi:10.1177/1073274821997430 · Cited by 67
RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)
Wong, M. K., Milhem, M. M., Sacco, J. J., Michels, J., In, G. K., Muñoz‐Couselo, E., Schadendorf, D., Beasley, G. M., Niu, J., Chmielowski, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01346 · Cited by 54
Immunomodulatory Peptides for Tumor Treatment
Song, Y., Lei, L., Cai, X., Wei, H., & Yu, C. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400512 · Cited by 29
Hu, L., Fan, C., Bross, P. F., Das, A., Cho, E. S., Knudson, K. M., Tegenge, M. A., Gao, Q., Brewer, J. R., Theoret, M. R., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0880 · Cited by 26
Yap, T. A., Sweis, R. F., Vaishampayan, U. N., Kilari, D., Gainor, J. F., McKean, M. A., Barve, M. A., Tarhini, A. A., Bockorny, B., Sonpavde, G., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04157-w · Cited by 14
Smestad, J. A., Rieth, J. M., Laux, D. E., & Milhem, M. M. (2025) · Cells · doi:10.3390/cells14201620 · Cited by 10
The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
Dean, N. J., d’Arienzo, P. D., Ibraheim, H., Lee, K. A., Olsson-Brown, A. C., Pinato, D. J., & Powell, N. (2024) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2024.101944 · Cited by 8
Immune Characters and Plasticity of the Sentinel Lymph Node in Colorectal Cancer Patients
Li, X., Tang, J., Du, H., Wang, X., Wu, L., Hu, P., Zhang, H., Zhang, R., & Yang, Y. (2021) · Journal of Immunology Research · doi:10.1155/2021/5516399 · Cited by 7
Microenvironment and Immunology of the Human Pleural Malignant Mesothelioma
Digifico, E., Belgiovine, C., Mantovani, A., & Allavena, P. (2019) · Springer eBooks · doi:10.1007/978-3-030-16884-1_5 · Cited by 5
The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma
Vestergaard, C. D., Ellebæk, E., Borch, T. H., Donia, M., & Svane, I. M. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00969-1 · Cited by 4
Programmable nucleic acid origami nanostructures for immunotherapy
Jia, J., Liu, X., & Chen, C. (2025) · Smart Materials in Medicine · doi:10.1016/j.smaim.2025.11.004 · Cited by 2
Yang, L., Liu, S., He, W., Xiong, Z., & Xia, L. (2023) · BMC Cancer · doi:10.1186/s12885-023-10610-1 · Cited by 2
Duan, X., Du, H., Qi, R., Yuan, M., & Shi, J. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11915 · Cited by 2
Golčić, M., Simetić, L., Majnarić, T., Golčić, G., & Herceg, D. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2022.110801 · Cited by 2
Persuaded, Not Certain: Why I Voted Yes
Miller, D. M. (2026) · Journal of Cutaneous Oncology · doi:10.59449/joco.2026.08.07 · Cited by 1
Frandsen, E. V., Hvas, C. L., Baunwall, S. M. D., Friis, R. B., Guldbrandt, L. M., & Schmidt, H. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102152
Metadata
- Authors
- Ribas, A., Kirkwood, J. M., & Flaherty, K. T.
- Affiliations
- University of California, Los Angeles (US)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Ribas, Antoni
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 19
- Issue
- 5
- Pages
- e219
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2800340935
- Cited by
- 20
- References
- 3
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 1
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, disease progression, RECIST, objective response rate, tumor regression, individual patient data, advanced melanoma
- MeSH terms
- Ipilimumab, Humans, Melanoma, United States Food and Drug Administration, Programmed Cell Death 1 Receptor, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
